Restricted or Liberal Antibiotics After Appendectomy - Denver Health
Launched by DENVER HEALTH AND HOSPITAL AUTHORITY · Aug 4, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Restricted or Liberal Antibiotics After Appendectomy," is looking at how the amount of antibiotics given after surgery for appendicitis affects patients. Researchers want to find out if using fewer antibiotics can help reduce side effects while still keeping patients safe. The trial is open to adults aged 18 and older who are scheduled for surgery to remove their appendix, whether the condition is simple or more complicated, like a perforated appendix.
If you participate, you will be part of a study that helps researchers understand the best antibiotic approach after your surgery. To join, you need to have a way for the medical team to contact you after your hospital stay. However, certain individuals, like those who are pregnant, have severe immune issues, or are still receiving treatment for other serious conditions, won't be eligible. The goal of this study is not only to improve patient care but also to ensure that your recovery is as smooth as possible.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Planned appendectomy (laparoscopic or open) for simple or complicated (perforated or gangrenous) appendicitis
- • Working telephone number or reliable method to contact patient after hospital discharge
- Exclusion Criteria:
- • Unable to consent
- • Pregnant Women
- • Prisoners
- • Immunocompromised as determined by clinical team, or patients actively receiving steroids, chemotherapy, or immunosuppressing medications (for example tacrolimus), or patients with active hematologic malignancy affecting the immune system, leukopenia, or end-stage AIDS
- • Heart failure
- • Allergy to bupivacaine
- • Unlikely to comply with treatment or follow-up
- • Inpatient consultation for appendicitis
- • Clinically suspected of sepsis based on Sepsis-3 definition
- • Current use of antibiotics for other indications
- • Uncontrolled hyperglycemia or Type 1 Diabetes
- • Surgeon preference
- • Patient preference
- • Research team unavailable
About Denver Health And Hospital Authority
Denver Health and Hospital Authority is a leading integrated healthcare system dedicated to providing high-quality medical care and advancing public health through innovative research and clinical trials. As a prominent academic medical center, Denver Health combines comprehensive patient services with a commitment to medical education and community outreach. The organization plays a vital role in advancing healthcare solutions by conducting rigorous clinical trials that aim to improve patient outcomes and address pressing health challenges. With a focus on collaboration and ethical standards, Denver Health is dedicated to enhancing the understanding of disease and treatment efficacy through its robust research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Boston, Massachusetts, United States
San Francisco, California, United States
Louisville, Kentucky, United States
Denver, Colorado, United States
El Paso, Texas, United States
Charlotte, North Carolina, United States
Falls Church, Virginia, United States
Brooklyn, New York, United States
Concord, North Carolina, United States
Miami, Florida, United States
New York, New York, United States
Fort Worth, Texas, United States
Patients applied
Trial Officials
Daniel D Yeh, MD, MHPE
Principal Investigator
Denver Health and Hospital Authority
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials